| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Hemab Therapeutics Holdings, Inc.$29.52
+0.37 (+1.27%)
D 29Pipeline Score Richly Valued Biotech · Clinical
Market Cap
1.21 B
EPS
-
P/E Ratio
-
Value Trade
5.61 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
19.46 M
Operating CF
-21.58 M
Total Assets
175.26 M
Total Liabilities
13.71 M
Equity
-198.62 M
D/E Ratio
12,345
-8.71 %
Week
-16.13 %
1 Month
-16.13 %
3 Month
-16.13 %
6 Month
-16.13 %
5 Year
-16.13 %
All Time
Cash Data
Cash Position
163.53 M
Monthly Burn
7.20 M
Runway
21.8 mo
Burn Trend
SEC Filing
May 21, 2026
Overview
Volume
86.83 K
52 Week Range
23.00 - 32
% held by Insiders
28.79 %
% held by Institutions
32.9 %
Enterprise Value
1.41 B
Total Shares
39.25 M
Short %
3.09 %
Float Shares
15.97 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D29
Pipeline Score $110M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 33%
Micro Cap (rank 607 of 905)
Percentile RankHemab Therapeutics Holdings, Inc. faces pipeline headwinds (29/100), with $333M risk-adjusted pipeline value, led by Sutacimig in Congenital Factor VII Deficiency (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sutacimig Small molecule | Congenital Factor VII Deficiency | Phase 2 | NCT07347249 | 23% | $252M | RECRUITING | 18 | AVERAGE | D (28) | Jul 1, 2026 | - | LOW May 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COAG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
COAG
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COAG
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COAG
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COAG Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
COAG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
COAGHemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Hemab Therapeutics will participate in the 2026 Jefferies Global Healthcare Conference, where its management team will present and hold investor meetings. The event is scheduled for June 4, 2026, in New York, NY. Hemab is focused on developing therapies for blood coagulation disorders, including treatments for Glanzmann thrombasthenia and Von Willebrand Disease.
Read more →COAGHemab Therapeutics Reports First Quarter 2026 Financial Results Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for s
Hemab Therapeutics has reported its first quarter financial results for 2026, highlighting the successful completion of an initial public offering that raised $346.7 million and secured a listing on Nasdaq. The company received Breakthrough Therapy Designation for sutacimig, a bispecific antibody for Glanzmann thrombasthenia. Despite these advancements, Hemab reported a net loss of $22.687 million in the quarter, with a decrease in cash reserves compared to the previous quarter.
Read more →COAGHemab Therapeutics Announces Pricing of Upsized Initial Public Offering
Hemab Therapeutics Holdings, Inc. has announced the pricing of its initial public offering, offering 16,750,000 shares at $18.00 each. The IPO is expected to generate around $301.5 million in gross proceeds. Trading is set to begin on the Nasdaq Global Select Market under the ticker 'COAG' on May 1, 2026, with the offering closing around May 4, 2026.
Read more →Competitive Position
How COAG ranks across every disease it competes inCompetitive Position is a premium feature
See how COAG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial